Background Background Few studies have
Few studies have examined the relative risks of switching examined the relative risks of switching into hypomania or mania associated with into hypomania or mania associated with second-generation antidepressant drugs second-generation antidepressant drugs in bipolar depression. in bipolar depression.
Aims Aims To examine the relative acute
To examine the relative acute effects of bupropion, sertraline and effects of bupropion, sertraline and venlafaxine as adjuncts to mood venlafaxine as adjuncts to mood stabilisers. stabilisers.
Method Method In a10 -week trial, participants
In a10 -week trial, participants receiving out-patienttreatment for bipolar receiving out-patienttreatment for bipolar disorder (stratified for rapid cycling) were disorder (stratified for rapid cycling) were randomly treated with a flexible dose of randomly treated with a flexible dose of one of the antidepressants, or their one of the antidepressants, or their respective matching placebos, as adjuncts respective matching placebos, as adjuncts to mood stabilisers. to mood stabilisers.
Results

Results Atotal of174 adults with
Atotal of174 adults with bipolar disorder I,II or not otherwise bipolar disorder I,II or not otherwise specified, currently in the depressed specified, currently in the depressed phase, were included. All three phase, were included. All three antidepressants were associated with a antidepressants were associated with a similar range of acute response (49^53%) similar range of acute response (49^53%) and remission (34^41%).There was a and remission (34^41%).There was a significantly increased risk of switches into significantly increased risk of switches into hypomania or mania in participants hypomania or mania in participants treated with venlafaxine compared with treated with venlafaxine compared with bupropion or sertraline. bupropion or sertraline.
Conclusions Conclusions More caution appears
More caution appears indicated in the use of venlafaxine rather indicated in the use of venlafaxine rather than bupropion or sertraline in the than bupropion or sertraline in the adjunctive treatment of bipolar adjunctive treatment of bipolar depression, especially if there is a prior depression, especially if there is a prior history of rapid cycling. history of rapid cycling.
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Bipolar disorder occurs in 1-3% of the Bipolar disorder occurs in 1-3% of the population (Angst & Sellaro, 2000; Akiskal population (Angst & Sellaro, 2000; Akiskal et al et al, 2000) . Despite naturalistic treatment , 2000) . Despite naturalistic treatment in the community or intensive treatment in the community or intensive treatment at academic centres, patients remain sympat academic centres, patients remain symptomatic approximately half of the year, and tomatic approximately half of the year, and the time depressed exceeds the time manic the time depressed exceeds the time manic or hypomanic by a factor of three (Judd or hypomanic by a factor of three (Judd et et al al, 2002; Post , 2002; Post et al et al, 2003 Post et al et al, , 2003a Kupka ; Kupka et al et al, , 2005) . Bipolar disorder is potentially lethal, 2005). Bipolar disorder is potentially lethal, with a 10-20% lifetime risk of dying by with a 10-20% lifetime risk of dying by suicide (Goodwin & Jamison, 1990) . suicide (Goodwin & Jamison, 1990) .
Despite these staggering human and Despite these staggering human and public health statistics, there have been public health statistics, there have been relatively few controlled studies of the use relatively few controlled studies of the use of antidepressants in the treatment of acute of antidepressants in the treatment of acute bipolar depression (Cohn bipolar depression (Cohn et al et al, 1989; , 1989; Himmelhoch Himmelhoch et al et al, 1991; Young , 1991; Young et al et al, , 2000; Nemeroff 2000; Nemeroff et al et al, 2001 ) compared with , 2001) compared with numerous controlled trials in unipolar denumerous controlled trials in unipolar depression. There has been one moderately pression. There has been one moderately sized ( sized (n n¼60) randomised, single-blind 60) randomised, single-blind study comparing the efficacy of paroxetine study comparing the efficacy of paroxetine and venlafaxine (Vieta and venlafaxine (Vieta et al et al, 2002) in bi-, 2002) in bipolar depression. A small comparative trial polar depression. A small comparative trial by Sachs by Sachs et al et al (1994) suggested that bupro- (1994) suggested that bupropion -which increases brain dopamine pion -which increases brain dopamine levels in the dorsal and ventral striatum levels in the dorsal and ventral striatum upon acute and chronic administration upon acute and chronic administration (Nomikos (Nomikos et al et al, 1989 (Nomikos et al et al, , 1992 (Nomikos et al et al, ) and also , 1989 (Nomikos et al et al, , 1992 and also possesses some effects on noradrenalinepossesses some effects on noradrenalineshowed comparable acute efficacy to the showed comparable acute efficacy to the noradrenergic tricyclic antidepressant desinoradrenergic tricyclic antidepressant desipramine, when added to ongoing treatment pramine, when added to ongoing treatment with a mood stabiliser for acute treatment with a mood stabiliser for acute treatment of bipolar depression. However, the rate of bipolar depression. However, the rate of switching into mania or hypomania on of switching into mania or hypomania on desipramine during acute and continuation desipramine during acute and continuation treatment was considerably higher (37.5%) treatment was considerably higher (37.5%) compared with bupropion (13.3%) (Guille compared with bupropion (13.3%) (Guille et al et al, 1999) . These data suggested the poss-, 1999). These data suggested the possibility that either the anticholinergic effects ibility that either the anticholinergic effects associated with the older tricyclic comassociated with the older tricyclic compounds in general or the potent selective pounds in general or the potent selective effects of desipramine on noradrenaline reeffects of desipramine on noradrenaline reuptake could account for these differences. uptake could account for these differences. Gijsman Gijsman et al et al (2004) in a meta-analysis (2004) in a meta-analysis found comparable efficacy but higher found comparable efficacy but higher switch rates for tricyclic antidepressants switch rates for tricyclic antidepressants compared with the newer antidepressants compared with the newer antidepressants in acute trials for bipolar depression. in acute trials for bipolar depression.
Based on the early study of Sachs Based on the early study of Sachs et al et al (1994) , we predicted that the three anti-(1994), we predicted that the three antidepressants bupropion, sertraline and depressants bupropion, sertraline and venlafaxine would achieve equal rates of venlafaxine would achieve equal rates of response, but that venlafaxine (like desipraresponse, but that venlafaxine (like desipramine) would show a higher rate of switchmine) would show a higher rate of switching into hypomania or mania because of ing into hypomania or mania because of its additional noradrenergic effects. Consisits additional noradrenergic effects. Consistent with the latter hypothesis, the study of tent with the latter hypothesis, the study of Vieta Vieta et al et al (2002) found an increased rate (2002) found an increased rate of switching on venlafaxine (13.3%) in a of switching on venlafaxine (13.3%) in a single-blind, randomised comparison with single-blind, randomised comparison with paroxetine (3.0%) for 6 weeks in bipolar paroxetine (3.0%) for 6 weeks in bipolar depression. depression.
METHOD METHOD
This study was a 10-week randomised trial This study was a 10-week randomised trial of 184 patients comparing bupropion, serof 184 patients comparing bupropion, sertraline and venlafaxine as adjuncts to one traline and venlafaxine as adjuncts to one or more mood stabilisers. Because of the or more mood stabilisers. Because of the anticipated prolonged unavailability of anticipated prolonged unavailability of one set of masked compounds at study outone set of masked compounds at study outset, the first 28 patients were randomised set, the first 28 patients were randomised by a data-coordinating centre in Bethesda by a data-coordinating centre in Bethesda but were treated with open medications at but were treated with open medications at each site; the next 156 patients were stueach site; the next 156 patients were studied in a randomised, double-blind fashion. died in a randomised, double-blind fashion. Each of the three drugs had an identically Each of the three drugs had an identically matched placebo and all patients took two matched placebo and all patients took two sets of compounds throughout this study sets of compounds throughout this study (one active and one placebo).
(one active and one placebo).
The study method has been previously The study method has been previously described for a smaller subgroup of these described for a smaller subgroup of these patients in an interim analysis of the overall patients in an interim analysis of the overall response and switch rates into hypomania response and switch rates into hypomania or mania of the antidepressants as a group or mania of the antidepressants as a group prior to unmasking the data (Post prior to unmasking the data (Post et al et al, , 2001 (Post et al et al, , 2001a . This is the report of the response ). This is the report of the response and switch rates of each of the three sepaand switch rates of each of the three separate antidepressants, and it includes the rate antidepressants, and it includes the entire cohort of patients randomised to entire cohort of patients randomised to the first acute phase of adjunctive treatment the first acute phase of adjunctive treatment of bipolar depression. of bipolar depression.
Patients were included when they met Patients were included when they met criteria for DSM-IV bipolar depression criteria for DSM-IV bipolar depression (American Psychiatric Association, 1994) (American Psychiatric Association, 1994) and had an Inventory of Depression Sympand had an Inventory of Depression Symptomatology (IDS; Rush tomatology (IDS; Rush et al et al, 1986 Rush et al et al, , 1996 Rush et al et al, ) , 1986 Rush et al et al, , 1996 scale score of at least 16; a Clinical Global scale score of at least 16; a Clinical Global Impression scale for Bipolar Disorder Impression scale for Bipolar Disorder (CGI-BP; Spearing (CGI-BP; Spearing et al et al, 1997) depression , 1997) depression severity score of at least 3; or the decision severity score of at least 3; or the decision on the part of the physician of a need to on the part of the physician of a need to treat the depressive episode because of its treat the depressive episode because of its functional impact. Most of these patients functional impact. Most of these patients were also rated for severity of depression were also rated for severity of depression and mania on a daily basis on the National and mania on a daily basis on the , 1978 ) score of at least 14 or a CGI-BP mania severity at least 14 or a CGI-BP mania severity score of at least 3 -at baseline were exscore of at least 3 -at baseline were excluded from the study, leaving a sample of cluded from the study, leaving a sample of 174 patients. The antidepressants were 174 patients. The antidepressants were added to an average of 1.4 other mood added to an average of 1.4 other mood stabilisers or antimanic agents. These medistabilisers or antimanic agents. These medications included lithium (64 patients All the patients who were randomised All the patients who were randomised had a depressive episode despite ongoing had a depressive episode despite ongoing treatment with one or more mood stabilitreatment with one or more mood stabilisers within specified dosage and therapeutic sers within specified dosage and therapeutic blood level guidelines. The minimum blood blood level guidelines. The minimum blood level guidelines for the mood stabilisers level guidelines for the mood stabilisers were 0.7 mmol/l for lithium, 50 were 0.7 mmol/l for lithium, 50 m mg/ml for g/ml for valproate and 4 valproate and 4 m mg/ml for carbamazepine. g/ml for carbamazepine. Dosages of these drugs, as well as of typical Dosages of these drugs, as well as of typical or atypical antipsychotics, or ongoing or atypical antipsychotics, or ongoing benzodiazepines in prophylaxis, were held benzodiazepines in prophylaxis, were held steady during the course of the protocol steady during the course of the protocol except for dose reductions because of sideexcept for dose reductions because of sideeffects. However, acute augmentation with effects. However, acute augmentation with benzodiazepines or chloral hydrate for a benzodiazepines or chloral hydrate for a maximum of 7 days was allowed for relief maximum of 7 days was allowed for relief of initial treatment-emergent insomnia or of initial treatment-emergent insomnia or anxiety. anxiety.
All patients were participants in the , 2001 ). All patients provided written informed consent tients provided written informed consent for participation in the Network in general, for participation in the Network in general, and additional specific written informed and additional specific written informed consent for participation in this randomised consent for participation in this randomised clinical trial as approved by each local insticlinical trial as approved by each local institutional review board. In the randomistutional review board. In the randomisation, the patients were stratified on the ation, the patients were stratified on the basis of presence or absence of a prior hisbasis of presence or absence of a prior history of DSM-IV-defined rapid cycling in tory of DSM-IV-defined rapid cycling in the year prior to study entry. At the the year prior to study entry. At the European sites in The Netherlands and European sites in The Netherlands and Germany, patients were randomised only Germany, patients were randomised only between sertraline and venlafaxine because between sertraline and venlafaxine because bupropion was not approved or available in bupropion was not approved or available in these countries. these countries.
The antidepressants were titrated The antidepressants were titrated towards maximum dosages based on sidetowards maximum dosages based on sideeffects tolerability and clinical discretion effects tolerability and clinical discretion during the 10-week acute trial. Starting during the 10-week acute trial. Starting and maximal dosages respectively for each and maximal dosages respectively for each compound were: bupropion 75-450 mg/ compound were: bupropion 75-450 mg/ day, sertraline 50-200 mg/day and day, sertraline 50-200 mg/day and venlafaxine 37.5-375 mg/day. venlafaxine 37.5-375 mg/day.
Patients were seen weekly for 2 weeks Patients were seen weekly for 2 weeks and then every 2 weeks for the duration of and then every 2 weeks for the duration of the 10-week acute-treatment trial. Symptom the 10-week acute-treatment trial. Symptom assessments were conducted using the IDS, assessments were conducted using the IDS, the YMRS and the CGI-BP at each visit. the YMRS and the CGI-BP at each visit. The CGI-BP part I, or severity scale, paralThe CGI-BP part I, or severity scale, parallels that of the original CGI, but the new forlels that of the original CGI, but the new format allows separate ratings for severity of mat allows separate ratings for severity of depression, mania and overall illness. The depression, mania and overall illness. The scale ranges are 1 not ill, 2 minimally ill, 3 scale ranges are 1 not ill, 2 minimally ill, 3 mildly ill, 4 moderately ill, 5 markedly ill, mildly ill, 4 moderately ill, 5 markedly ill, 6 severely ill and 7 very severely ill. 6 severely ill and 7 very severely ill.
Although those not responding to antiAlthough those not responding to antidepressant therapy were subsequently depressant therapy were subsequently offered re-randomisation to another antioffered re-randomisation to another antidepressant (Post depressant (Post et al et al, 2001 , 2001a a; Leverich ; Leverich et et al al, 2006) , the analysis in this report only , 2006), the analysis in this report only considered the first parallel-group randomconsidered the first parallel-group randomised phase, so that all patients would be ised phase, so that all patients would be represented only once and data would be represented only once and data would be suitable for independent statistics. All data suitable for independent statistics. All data presented represent the intention-to-treat presented represent the intention-to-treat analysis. analysis.
Three outcome variables were assessed: Three outcome variables were assessed: antidepressant response, antidepressant reantidepressant response, antidepressant remission and antidepressant-related switch mission and antidepressant-related switch into mania or hypomania. Response was into mania or hypomania. Response was operationalised as either a 50% or greater operationalised as either a 50% or greater improvement in IDS score, or a decrease improvement in IDS score, or a decrease in the CGI-BP depression score of at least in the CGI-BP depression score of at least 2 points. Response rates were reported at 2 points. Response rates were reported at the study end-point and the time to the study end-point and the time to response was calculated for each drug. response was calculated for each drug. Remission criteria included an IDS score Remission criteria included an IDS score below 12 and/or a CGI-BP depression below 12 and/or a CGI-BP depression severity score of 1 (normal, not ill) at study severity score of 1 (normal, not ill) at study end-point. A switch into hypomania or end-point. A switch into hypomania or mania was operationalised as either a 2-mania was operationalised as either a 2-point increase at any point in the trial on point increase at any point in the trial on the CGI-BP (suggesting a clinically meanthe CGI-BP (suggesting a clinically meaningful switch), or a CGI-BP manic severity ingful switch), or a CGI-BP manic severity score of at least 3 (i.e. at least mildly manic) score of at least 3 (i.e. at least mildly manic) or a YMRS score above 13 at any visit. or a YMRS score above 13 at any visit.
Statistical analysis Statistical analysis
The Stanley Foundation Bipolar Network The Stanley Foundation Bipolar Network ended in 2002 and the analysis of these ended in 2002 and the analysis of these data was supported by the Stanley Research data was supported by the Stanley Research Medical Institute. The core data repository Medical Institute. The core data repository was transferred from the data coordinating was transferred from the data coordinating centre in Bethesda to the University of centre in Bethesda to the University of California at Los Angeles where analyses California at Los Angeles where analyses for this study were conducted. The patients for this study were conducted. The patients were entered into this study at the seven were entered into this study at the seven different sites beginning in March 1996 different sites beginning in March 1996 and ending in November 2002. and ending in November 2002.
When demographic data, response rates When demographic data, response rates and switch rates were analysed separately and switch rates were analysed separately for the 27 open and 147 masked randomifor the 27 open and 147 masked randomisations, they were not found to be statisations, they were not found to be statistically significantly different (details stically significantly different (details available in the data supplement to the onavailable in the data supplement to the online version of this paper). Therefore, the line version of this paper). Therefore, the data are presented for the combined analydata are presented for the combined analysis of the 174 patients for simplicity of presis of the 174 patients for simplicity of presentation and in order to have maximum sentation and in order to have maximum power for detecting differences in switch power for detecting differences in switch rates among the three antidepressant drugs. rates among the three antidepressant drugs. This was felt to be justified because our inThis was felt to be justified because our initial hypothesis was that there would be no itial hypothesis was that there would be no significant difference in initial degrees of significant difference in initial degrees of acute responsiveness among these three acute responsiveness among these three antidepressants, but as in the Sachs antidepressants, but as in the Sachs et al et al (1994) data for desipramine, venlafaxine (1994) data for desipramine, venlafaxine would have a higher switch rate than the would have a higher switch rate than the other two drugs. other two drugs.
Kaplan-Meier curves were used to conKaplan-Meier curves were used to construct survival curves among the treatment struct survival curves among the treatment arms in time-to-event data. Differences arms in time-to-event data. Differences in strata were assessed using the log-rank in strata were assessed using the log-rank test. Chi-squared tests were used to assess test. Chi-squared tests were used to assess significance for categorical data. significance for categorical data.
RESULTS RESULTS
Patient characteristics are summarised in Patient characteristics are summarised in Table 1 and the flow of patients is show  Table 1 and the flow of patients is show in Fig. 1 . Participants showed balanced in Fig. 1 . Participants showed balanced gender distribution, were an average of gender distribution, were an average of 41.7 years of age and had 19.1 years 41.7 years of age and had 19.1 years of illness, averaging 14.3 prior episodes of illness, averaging 14.3 prior episodes of depression and 12.2 prior episodes of of depression and 12.2 prior episodes of mania. The majority (73%) of diagnoses mania. The majority (73%) of diagnoses were bipolar I disorder, 26% were bipolar were bipolar I disorder, 26% were bipolar II disorder and 1% bipolar disorder not II disorder and 1% bipolar disorder not otherwise specified. More than a quarter otherwise specified. More than a quarter (27%) had a prior history of rapid cycling. (27%) had a prior history of rapid cycling. Fifty-one patients were randomised to Fifty-one patients were randomised to receive bupropion, 58 to sertraline and 65 receive bupropion, 58 to sertraline and 65 to venlafaxine. 112) mg for venlafaxine. About a third of the patients withdrew About a third of the patients withdrew from the trial prematurely, for lack of from the trial prematurely, for lack of improvement or worsening mood, includimprovement or worsening mood, including 29% of those taking bupropion ing 29% of those taking bupropion ( (n n¼15), 28% taking sertraline ( 15), 28% taking sertraline (n n¼16) and 16) and 38% taking venlafaxine ( 38% taking venlafaxine (n n¼25) ( Table 2) . 25) ( Table 2 ). Other withdrawals for side-effects or adOther withdrawals for side-effects or administrative reasons did not differ among ministrative reasons did not differ among the three drugs. the three drugs.
Overall, the percentage of patients who Overall, the percentage of patients who left the study prior to 10 weeks for any realeft the study prior to 10 weeks for any reason was 31% of those taking bupropion, son was 31% of those taking bupropion, 41% of those taking sertraline and 45% 41% of those taking sertraline and 45% of those taking venlafaxine. of those taking venlafaxine.
Response and remission rates Response and remission rates
At week 10, using the IDS or CGI-BP At week 10, using the IDS or CGI-BP criterion, response rates were 49% for criterion, response rates were 49% for bupropion, 53% for sertraline and 51% bupropion, 53% for sertraline and 51% for venlafaxine; remission rates (either IDS for venlafaxine; remission rates (either IDS score score 4 412 or CGI-BP score 12 or CGI-BP score¼1) were 1) were 41%, 36% and 34% respectively (Table  41% , 36% and 34% respectively (Table  3) . There was no significant difference 3). There was no significant difference between the groups. To evaluate if cobetween the groups. To evaluate if cotreatment with lithium influenced these treatment with lithium influenced these results a log linear model was fitted to the results a log linear model was fitted to the data. The inclusion of a relationship data. The inclusion of a relationship between lithium and response or remission between lithium and response or remission did not improve the fit of the log linear did not improve the fit of the log linear model 
Switch rates Switch rates
Most patients did not switch into hypomaMost patients did not switch into hypomania or mania when prescribed acute adjuncnia or mania when prescribed acute adjunctive antidepressant therapy, regardless of tive antidepressant therapy, regardless of the antidepressant prescribed. However, the antidepressant prescribed. However, on most measures and analyses venlafaxine on most measures and analyses venlafaxine showed a higher risk of patients switching showed a higher risk of patients switching into hypomania or mania than bupropion into hypomania or mania than bupropion or sertraline. Using the requirement of a or sertraline. Using the requirement of a 2-point or greater increase on the CGI-BP 2-point or greater increase on the CGI-BP mania severity rating, switching occurred mania severity rating, switching occurred in 10% of patients taking bupropion, 9% in 10% of patients taking bupropion, 9% taking sertraline, and 29% taking venlafaxtaking sertraline, and 29% taking venlafaxine. To control for the effect of withdrawals ine. To control for the effect of withdrawals on the relative risk of switching, these data on the relative risk of switching, these data were analysed using survival analysis (Fig. were analysed using survival analysis (Fig.  2) . Results revealed a significant overall 2). Results revealed a significant overall difference between the three groups (log difference between the three groups (log rank rank w w analysis of this result demonstrated that the effect was mainly driven by a sigthat the effect was mainly driven by a significant difference in the risk of switching nificant difference in the risk of switching Using the more conservative YMRS Using the more conservative YMRS threshold score of threshold score of 4 413, only 4% of 13, only 4% of patients on bupropion and 7% of patients patients on bupropion and 7% of patients on sertraline switched into hypomania or on sertraline switched into hypomania or mania by study end-point, but 15% of mania by study end-point, but 15% of patients on venlafaxine had switched by patients on venlafaxine had switched by study end-point (log rank study end-point (log rank w w ¼5.80, d.f. 5.80, d.f.¼2, 2, P P¼0.055). 0.055). Using the combined switch criterion of Using the combined switch criterion of CGI-BP severity of mania CGI-BP severity of mania 5 53 or 3 or YMRS YMRS4 413, the switch rate of the bupro-13, the switch rate of the bupropion group was 14%, the switch rate of pion group was 14%, the switch rate of the sertraline group was 16% and the the sertraline group was 16% and the switch rate for venlafaxine was 31%. This switch rate for venlafaxine was 31%. This difference was significant both when difference was significant both when lithium was not included (log rank lithium was not included (log rank w w 2 2 ¼7.33, d.f. 7.33, d.f.¼2, 2, P P¼0.03) and when 0.03) and when lithium was included (log rank lithium was included (log rank w w 2 2 ¼7.55, 7.55, d.f. d.f.¼2, 2, P P¼0.02). The results of a 0.02). The results of a post hoc post hoc analysis again showed that the difference analysis again showed that the difference was driven by venlafaxine. The hazard for was driven by venlafaxine. The hazard for switching was not significantly different switching was not significantly different between bupropion and sertraline after between bupropion and sertraline after adjustment for lithium (log rank adjustment for lithium (log rank w w 2 2 ¼0.38, 0.38, d.f. d.f.¼1, 1, P P¼0.54), whereas the patients 0.54), whereas the patients treated with venlafaxine experienced signiftreated with venlafaxine experienced significantly higher switch rates than the patients icantly higher switch rates than the patients 12 8 12 8 Table 3  Table 3 Rates of antidepressant response, remission and switching into hypomania or mania Rates of antidepressant response, remission and switching into hypomania or mania (49) 25 (49) 31 (53) 31 (53) 33 (51) 33 (51) 89 (51) (4) 4 (7) 4 (7) 10 (15) 10 (15) 16 (9) 16 (9) log rank log rank w w (10) 5 (9) 5 (9) 19 (29) 19 (29) 29 (17) 29 (17) log rank log rank w w 
Rapid cycling Rapid cycling
There was a strong interaction between the There was a strong interaction between the rapid-cycling status of patients and the relarapid-cycling status of patients and the relative risk of switching for the three meditive risk of switching for the three medication groups. In those without rapidcation groups. In those without rapidcycling disorder the risk of switching was cycling disorder the risk of switching was identical for all three medication groups identical for all three medication groups (log rank (log rank w w 2 2 .197, d.f. 1.197, d .f.¼2, 2, P P¼0.55), but 0.55), but the difference between the three medicathe difference between the three medications was highly significant among rapidtions was highly significant among rapidcycling patients (log rank cycling patients (log rank w w 2 2 ¼9.66, d.f. 9.66, d.f.¼2, 2, P P5 50.01). The pattern of this difference 0.01). The pattern of this difference for the rapid-cycling group was the familiar for the rapid-cycling group was the familiar result that bupropion had a significantly result that bupropion had a significantly lower risk for switching than venlafaxine lower risk for switching than venlafaxine (log rank (log rank w w 2 2 ¼9.07, d.f. 9.07, d.f.¼1, 1, P P5 50.01), 0.01), whereas there was no significant difference whereas there was no significant difference between bupropion and sertraline (log rank between bupropion and sertraline (log rank w w 2 2 ¼1.9, d.f.
¼1
1.9, d.f.¼1, 1, P P¼0.17) or between sertra-0.17) or between sertraline and venlafaxine (log rank line and venlafaxine (log rank w w 
DISCUSSION DISCUSSION
Overall response and switch rates Overall response and switch rates on antidepressant augmentation on antidepressant augmentation
To our knowledge, this is the largest ranTo our knowledge, this is the largest randomised comparative study of the response domised comparative study of the response and switch rates of modern (i.e. non-tricycand switch rates of modern (i.e. non-tricyclic) antidepressants in the adjunctive treatlic) antidepressants in the adjunctive treatment of acute bipolar depression. All of ment of acute bipolar depression. All of these unimodal antidepressants are apthese unimodal antidepressants are approved by the US Food and Drug Adminisproved by the US Food and Drug Administration (FDA) for the treatment of major tration (FDA) for the treatment of major depression, but are not FDA-approved for depression, but are not FDA-approved for use in bipolar depression and are not widely use in bipolar depression and are not widely studied by European authorities. studied by European authorities. The three agents with different mechanThe three agents with different mechanisms of action were assessed for their relaisms of action were assessed for their relative magnitude of acute antidepressant tive magnitude of acute antidepressant response when added to ongoing treatment response when added to ongoing treatment with mood stabilisers in this 10-week trial. with mood stabilisers in this 10-week trial. Overall response (49-53%) and remission Overall response (49-53%) and remission rates (34-41%) were similar to those often rates (34-41%) were similar to those often seen in antidepressant monotherapy trials seen in antidepressant monotherapy trials in unipolar illness, using the traditional in unipolar illness, using the traditional 50% improvement and absolute criteria re-50% improvement and absolute criteria respectively. Substantial numbers of patients spectively. Substantial numbers of patients (31-45%) withdrew prematurely from the (31-45%) withdrew prematurely from the trial because of lack of improvement or trial because of lack of improvement or worsening of either depressed or manic worsening of either depressed or manic mood, indicating a continuing need to find mood, indicating a continuing need to find more effective agents for even the acute more effective agents for even the acute treatment of bipolar depression. treatment of bipolar depression.
Most patients in this acute treatment Most patients in this acute treatment trial did not switch into hypomania or mania trial did not switch into hypomania or mania with the addition of an antidepressant to with the addition of an antidepressant to their ongoing mood stabiliser regimen. their ongoing mood stabiliser regimen. Overall, across all medication groups, 9% Overall, across all medication groups, 9% switched by the more stringent criteria of switched by the more stringent criteria of YMRS score YMRS score 4 413 (Table 3) , whereas more 13 (Table 3) , whereas more than double that (21%) switched using the than double that (21%) switched using the CGI-BP severity score ( CGI-BP severity score (5 53) of at least mild 3) of at least mild mania. mania.
The CGI-BP cut-off of mild mania is a The CGI-BP cut-off of mild mania is a more permissive measure than the YMRS more permissive measure than the YMRS score, and this two-fold difference in what score, and this two-fold difference in what is categorised as a switch depending on is categorised as a switch depending on which scale or cut-off score is used needs which scale or cut-off score is used needs to be considered by investigators in the futo be considered by investigators in the future when designing trials and specifying ture when designing trials and specifying outcome measures. Use of different threshoutcome measures. Use of different threshold criteria may account for some of the old criteria may account for some of the large discrepancies in the field regarding large discrepancies in the field regarding reported switch rates. Similarly, the inclureported switch rates. Similarly, the inclusion or exclusion of patients with rapidsion or exclusion of patients with rapidcycling disorder in a study also contributes cycling disorder in a study also contributes to these differences in switch rates. to these differences in switch rates.
Switch rates among Switch rates among the three antidepressants the three antidepressants Venlafaxine had a greater risk for inducing Venlafaxine had a greater risk for inducing switching than the other two agents, i.e. switching than the other two agents, i.e. bupropion as a dopamine-active agent and bupropion as a dopamine-active agent and sertraline as a representative serotonin sesertraline as a representative serotonin selective reuptake inhibitor (SSRI) (Nomikos lective reuptake inhibitor (SSRI) (Nomikos et al et al, 1989 (Nomikos et al et al, , 1992 Ascher , 1989 Ascher , , 1992 Ascher et al et al, 1995) . , 1995). These data are consistent with those These data are consistent with those from the single-blind randomised study of from the single-blind randomised study of Vieta Vieta et al et al (2002) , who found a greater (2002), who found a greater switch risk for venlafaxine (mean dosage switch risk for venlafaxine (mean dosage 180 mg) compared with the SSRI paroxe-180 mg) compared with the SSRI paroxetine (mean dosage 30 mg), although patine (mean dosage 30 mg), although patients were only assessed for 6 weeks and tients were only assessed for 6 weeks and the YMRS criterion for a switch was a the YMRS criterion for a switch was a score of 11 as opposed to the 14 used here. score of 11 as opposed to the 14 used here. Nonetheless, the switch rates for venlafaxNonetheless, the switch rates for venlafaxine (13.3%) ine (13.3%) v.
v. paroxetine (3.0%) in that paroxetine (3.0%) in that study were of a similar magnitude to the study were of a similar magnitude to the switch rates in this study for venlafaxine switch rates in this study for venlafaxine (15.4%) (15.4%) v.
v. sertraline (6.9%). sertraline (6.9%). These findings could also be consistent These findings could also be consistent with the higher switch rates for the tricyclic with the higher switch rates for the tricyclic antidepressants (Gijsman antidepressants (Gijsman et al et al, 2004 (Gijsman et al et al, ) which , 2004 ) which represent largely combined serotonin and represent largely combined serotonin and noradrenaline reuptake inhibitors, or nornoradrenaline reuptake inhibitors, or noradrenaline selective ones (e.g. nortriptyline adrenaline selective ones (e.g. nortriptyline and desipramine). Sachs and desipramine). Sachs et al et al (1994) and (1994) and Guille Guille et al et al (1999) also found a higher switch (1999) also found a higher switch rate for desipramine than for bupropion. rate for desipramine than for bupropion.
Interestingly, in our study the greater Interestingly, in our study the greater switch rates on venlafaxine compared with switch rates on venlafaxine compared with the other drugs were largely accounted for the other drugs were largely accounted for by the increased switch risk in the rapidby the increased switch risk in the rapidcycling group, and those without rapidcycling group, and those without rapidcycling disorder did not show this cycling disorder did not show this differential risk. It is especially noteworthy differential risk. It is especially noteworthy that those with rapid-cycling disorder did that those with rapid-cycling disorder did not appear more switch-prone when exnot appear more switch-prone when exposed to bupropion or sertraline than those posed to bupropion or sertraline than those with the non-rapid-cycling form on these with the non-rapid-cycling form on these drugs, as many might have predicted (log drugs, as many might have predicted (log rank rank w w 2 2 ¼0.321, d.f. 0.321, d.f.¼1, 1, P P¼0.571). 0.571).
Methodological limitations Methodological limitations
This study has several methodological limThis study has several methodological limitations, including the combination of data itations, including the combination of data for the first 27 open randomised patients for the first 27 open randomised patients with the next 147 studied in a double-blind with the next 147 studied in a double-blind fashion. However, this did not have a fashion. However, this did not have a major impact on the observed rates of remajor impact on the observed rates of response, remission or switching. Generally sponse, remission or switching. Generally similar findings were observed when only similar findings were observed when only the 147 masked patients were included the 147 masked patients were included (further information available in the data (further information available in the data supplement to the online version of this supplement to the online version of this paper). paper). A problem not addressed by our study A problem not addressed by our study is the rate of response or switching related is the rate of response or switching related to antidepressant agents over that which to antidepressant agents over that which might occur naturally through course of illmight occur naturally through course of illness variation. It was decided not to include ness variation. It was decided not to include a placebo arm in this study to make it most a placebo arm in this study to make it most similar to naturalistic treatment in the comsimilar to naturalistic treatment in the community and to focus on comparison of munity and to focus on comparison of switch rates among the three agents. This switch rates among the three agents. This was also intended to enhance participant was also intended to enhance participant recruitment in an out-patient setting in recruitment in an out-patient setting in which a high percentage of patients were which a high percentage of patients were working full-time or part-time and generworking full-time or part-time and generally wished to be treated with active agents ally wished to be treated with active agents as rapidly as possible. Thus, we do not as rapidly as possible. Thus, we do not know with any degree of certainty whether know with any degree of certainty whether any of the antidepressants was efficacious, any of the antidepressants was efficacious, i.e. significantly more effective than plai.e. significantly more effective than placebo. This concern is also heightened by cebo. This concern is also heightened by the finding of Nemeroff the finding of Nemeroff et al et al (2001 Nemeroff et al et al ( ) that (2001 that the effectiveness of paroxetine did not the effectiveness of paroxetine did not exceed that of placebo when used as an exceed that of placebo when used as an adjunct to lithium (unless lithium levels adjunct to lithium (unless lithium levels were low). However, given that venlafaxine were low). However, given that venlafaxine was more likely to be associated with hypowas more likely to be associated with hypomania or mania than two other active drugs mania or mania than two other active drugs (bupropion or sertraline), it would appear (bupropion or sertraline), it would appear that venlafaxine carries an increased risk that venlafaxine carries an increased risk of switching compared with two other of switching compared with two other widely used antidepressants, especially in widely used antidepressants, especially in the treatment of patients with rapid-cycling the treatment of patients with rapid-cycling bipolar illness. This differential liability of bipolar illness. This differential liability of venlafaxine compared with two other acvenlafaxine compared with two other active comparators to some extent obviates tive comparators to some extent obviates the need for a placebo comparison group, the need for a placebo comparison group, at least in relation to the rate of switching at least in relation to the rate of switching on venlafaxine. on venlafaxine.
The study also did not address the optiThe study also did not address the optimal duration of antidepressant treatment, mal duration of antidepressant treatment, even though participants whose condition even though participants whose condition responded to therapy were offered contiresponded to therapy were offered continuation treatment on a masked basis (Post nuation treatment on a masked basis (Post et al et al, 2001 (Post et al et al, , 2001a (Post et al et al, a, 2003 (Post et al et al, , 2003b . However, based on ). However, based on data in three recent naturalistic studies data in three recent naturalistic studies (Altshuler (Altshuler et al et al, 2001 (Altshuler et al et al, , 2003 Joffe , 2001 Joffe , , 2003 Joffe et al et al, , 2005) , it has been suggested that for the 2005), it has been suggested that for the small minority of people with bipolar dissmall minority of people with bipolar disorder who both respond to acute antiorder who both respond to acute antidepressant treatment and remain well for depressant treatment and remain well for at least 6 weeks, continuation of the antiat least 6 weeks, continuation of the antidepressant medication over the following depressant medication over the following year may be superior to its discontinuation year may be superior to its discontinuation because it is associated with a reduction in because it is associated with a reduction in the occurrence of new depressive episodes the occurrence of new depressive episodes without any increase in switch rates into without any increase in switch rates into mania. However, interim results of a 5-year mania. However, interim results of a 5-year study of 33 patients (Ghaemi study of 33 patients (Ghaemi et al et al, 2005) , 2005) indicate that discontinuation of antidepresindicate that discontinuation of antidepressant may be either non-inferior or perhaps sant may be either non-inferior or perhaps slightly superior to antidepressant contislightly superior to antidepressant continuation, which appeared to increase affecnuation, which appeared to increase affective morbidity in non-rapid-cycling bipolar tive morbidity in non-rapid-cycling bipolar disorder. disorder.
Other limitations of this study include Other limitations of this study include the flexible dosage titration, such that the the flexible dosage titration, such that the rate of dosage increase and final levels rate of dosage increase and final levels achieved could have affected either reachieved could have affected either response rates or switch vulnerability. Howsponse rates or switch vulnerability. However, the relatively low maximum dosage ever, the relatively low maximum dosage of venlafaxine compared with the other of venlafaxine compared with the other two drugs suggests that the high switch rate two drugs suggests that the high switch rate on venlafaxine was not related to an overly on venlafaxine was not related to an overly aggressive dose titration of this drug aggressive dose titration of this drug compared with the others. compared with the others.
Strengths of this study include its Strengths of this study include its double-blind evaluation of 147 patients; double-blind evaluation of 147 patients; that the study was relatively large that the study was relatively large compared with many previous studies of compared with many previous studies of bipolar depression; that the 174 patients bipolar depression; that the 174 patients randomised to one of the three secondrandomised to one of the three secondgeneration antidepressants with different generation antidepressants with different mechanisms of action were sufficient to dismechanisms of action were sufficient to discern a significant difference in switching cern a significant difference in switching into hypomania or mania on venlafaxine into hypomania or mania on venlafaxine compared with bupropion and sertraline; compared with bupropion and sertraline; and that the sample was representative of and that the sample was representative of people receiving out-patient treatment, people receiving out-patient treatment, including those with a history of rapidincluding those with a history of rapidcycling disorder (Kupka cycling disorder (Kupka et al et al, 2005) . , 2005).
Clinical and research implications Clinical and research implications
Other study designs, such as that used Other study designs, such as that used by Young by Young et al et al (2000) in patients with (2000) in patients with non-rapid-cycling disorder, are now necesnon-rapid-cycling disorder, are now necessary to put these results in perspective, by sary to put these results in perspective, by examining the use of antidepressants with examining the use of antidepressants with a low risk of switch (i.e. bupropion, sertraa low risk of switch (i.e. bupropion, sertraline or a related SSRI) compared with a line or a related SSRI) compared with a second mood stabiliser (especially lamosecond mood stabiliser (especially lamotrigine) or an atypical antipsychotic, in trigine) or an atypical antipsychotic, in order to begin to develop an evidence-based order to begin to develop an evidence-based algorithm for the best approach to the algorithm for the best approach to the treatment of breakthrough bipolar treatment of breakthrough bipolar depression in both rapid-cycling and nondepression in both rapid-cycling and nonrapid-cycling disorder. Since time depressed rapid-cycling disorder. Since time depressed exceeds that of time manic by a factor of exceeds that of time manic by a factor of three in naturalistically treated out-patients three in naturalistically treated out-patients (Judd (Judd et al et al, 2002; Post , 2002; Post et al et al, 2003 Post et al et al, , 2003a ; Nolen Nolen et al et al, 2004; Kupka , 2004; Kupka et al et al, 2005) , such , 2005), such direct comparisons for effectiveness, direct comparisons for effectiveness, tolerability and switch risk would be timely tolerability and switch risk would be timely and potentially highly informative for and potentially highly informative for clinical practice. clinical practice.
The results of this study reveal nonThe results of this study reveal nonsignificantly different acute antidepressant significantly different acute antidepressant response and remission rates among the response and remission rates among the three mechanistically different secondthree mechanistically different secondgeneration antidepressants used adjuncgeneration antidepressants used adjunctively in the acute treatment of bipolar tively in the acute treatment of bipolar depression. However, there was a depression. However, there was a significantly increased risk of switching into significantly increased risk of switching into hypomania or mania on several measures hypomania or mania on several measures during acute treatment with venlafaxine during acute treatment with venlafaxine compared with bupropion or sertraline. compared with bupropion or sertraline. This was largely accounted for by the inThis was largely accounted for by the increased switch rate in the rapid-cycling creased switch rate in the rapid-cycling group taking venlafaxine. When daily group taking venlafaxine. When daily NIMH-LCM ratings were used, venla-NIMH-LCM ratings were used, venlafaxine also had a three times higher ratio faxine also had a three times higher ratio than bupropion of full duration/severity than bupropion of full duration/severity switches compared with brief hypomanias switches compared with brief hypomanias in the 1-year continuation phase of the in the 1-year continuation phase of the study, further suggesting that the increased study, further suggesting that the increased risk of a full switch on venlafaxine does not risk of a full switch on venlafaxine does not dissipate after the end of the 10-week acute dissipate after the end of the 10-week acute trial, as it tended to do for both bupropion trial, as it tended to do for both bupropion and sertraline (Leverich and sertraline (Leverich et al et al, 2006) . Clini-, 2006 ). Clinicians should be aware of the risk of hypocians should be aware of the risk of hypomania or mania for those prescribed mania or mania for those prescribed venlafaxine (especially those with a history venlafaxine (especially those with a history of four or more episodes in the prior year) of four or more episodes in the prior year) when considering the choice of antidepreswhen considering the choice of antidepressant for the common problem of bipolar sant for the common problem of bipolar depression breaking through ongoing treatdepression breaking through ongoing treatment with one or more mood stabilisers. ment with one or more mood stabilisers.
